Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RISE-CTEPH: Riociguat vs Selexipag in Chronic Thromboembolic Pulmonary Hypertension
jRCT1041210122Recruiting
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Riociguat arm with Selexipag arm (2 arms). Primary endpoint: Primary: Change in diagnostic parameters at 20 weeks. Started Jan 2021; status: recruiting.
02
Drugs
riociguatselexipag
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on jRCT1041210122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041210122.